|
Feb 24
|
Telix Pharmaceuticals Limited (TLX) Upgraded to Buy: What Does It Mean for the Stock?
|
|
Feb 21
|
Telix Pharmaceuticals Ltd (TLPPF) (FY 2024) Earnings Call Highlights: Record Revenue Growth and ...
|
|
Feb 20
|
Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion
|
|
Feb 13
|
Telix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025)
|
|
Feb 12
|
Illuccix® Approved in the United Kingdom
|
|
Feb 11
|
Is Telix Pharmaceuticals Limited (TLX) the Best Long Term ASX Stock to Buy Now?
|
|
Jan 30
|
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
|
|
Jan 27
|
Telix Completes Acquisition of RLS (USA) Inc.
|
|
Jan 13
|
Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference
|
|
Jan 13
|
Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
|
|
Jan 13
|
Scintimun® Commercialization Partnership with Curium Pharma
|
|
Jan 12
|
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
|
|
Dec 30
|
NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports
|
|
Dec 29
|
Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging
|
|
Oct 4
|
Health Canada Approves Label Expansion for Telix’s Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
|
|
Oct 3
|
First Patient Dosed in Phase II 'CA-NINE' Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
|
|
Jul 29
|
Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent
|
|
Jul 24
|
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
|
|
Jul 23
|
Telix Successfully Prices A$650 Million Convertible Bonds
|
|
Jul 23
|
Telix Announces A$600 Million Convertible Bonds Offering
|